Biomarker-Guided Immunosuppression Shows Safety in Kidney Transplant: TTVguideIT Phase II Trial Meets Primary Endpoint
核心洞察
A randomized Phase II trial across 13 European centers demonstrated that Torque-Teno virus (搜索) (TTV)-guided tacrolimus dosing is non-inferior to standard immunosuppression in kidney transplant recipients.
The composite primary endpoint of infections, graft rejection, graft loss, or death occurred in 35% of the TTV-guided group versus 38% in the control group, with comparable rejection rates at 12 months.
Patients in the TTV-guided arm received lower tacrolimus doses and achieved lower drug levels, suggesting immunosuppression reduction may be possible without compromising organ safety in low-risk patients.
An international research team coordinated by the Medical University of Vienna has demonstrated in a landmark clinical trial that Torque-Teno virus (搜索) (TTV)-guided dosing of immunosuppressants in kidney transplant recipients is safe and non-inferior to standard-of-care treatment. The results of the TTVguideIT study, presented at the annual congress of the European Society of Nephrology (ERA 26 in Glasgow), suggest that immunosuppressive therapy could be further personalized and reduced in certain patient groups, marking a significant advance in transplant medicine.
The study forms the central conclusion of the EU-funded Horizon 2020 project TTVguideTX, coordinated by Gregor Bond from the Division of Nephrology and Dialysis at the Department of Medicine III at MedUni Vienna.
The challenge of immunosuppression management
Following a kidney transplant, patients require long-term immunosuppressive medication to protect the transplanted organ from rejection. However, the therapeutic window is narrow: excessive immunosuppression elevates infection risk, while insufficient suppression can lead to organ damage or loss. Historically, dosing has been guided by fixed target drug levels in the blood, but these values provide only limited insight into how strongly an individual's immune system is actually suppressed.
The TTVguideIT study investigated whether TTV — a virus present in many people that does not cause disease — could serve as a biomarker to enable more individualized immunosuppression management. Low TTV levels may indicate an overactive immune system, while high levels may signal an underactive immune system.
"Our aim was to adjust immunosuppression not only according to fixed drug levels, but to align it more closely with the patients' actual immunological status," said Gregor Bond, overall coordinator of the project. "The study shows that TTV-guided adjustment of the dose of the immunosuppressive drug tacrolimus was safely possible in the patient group studied."
Trial design and primary results
The randomized, controlled Phase II study enrolled 260 adult, stable kidney transplant recipients with low immunological and infectious disease risk. Conducted at 13 academic centers across Austria, Germany, France, the Czech Republic, the Netherlands, and Spain, the trial randomized patients four months after transplantation to either TTV-guided tacrolimus dosing or standard treatment.
The primary endpoint was a composite of infections, graft rejection, graft loss, or death. In the TTV-guided group, this endpoint occurred in 35% of patients, compared with 38% in the control group — meeting the study's objective of demonstrating non-inferiority. Rejection rates in protocol biopsies after twelve months were comparable between both groups.
Notably, patients in the TTV-guided arm had lower tacrolimus levels and received lower daily doses. While a statistically significant reduction in infections was not demonstrated, the results suggest that in stable, low-risk patients, a reduction in immunosuppression may be possible without compromising the safety of the transplanted organ.
A milestone for academic transplant research
"The result is an important step towards personalized transplant medicine," said Bond. "TTV measurement is approved for clinical use, cost-effective, easy to measure and readily standardized. This approach therefore has the potential to be widely used in further clinical trials and, later, possibly in routine clinical practice."
The TTVguideIT study was part of the EU-funded Horizon 2020 project TTVguideTX, which received over six million euros in funding over five and a half years. A total of 20 partners from ten European countries were involved, including university transplant centers, virology, study coordination, ethics, biostatistics, and industry partners.
From an Austrian perspective, the project carried structural significance: it was the largest investigator-driven randomized clinical trial in Austria at the time, and for the first time, all four Austrian transplant centers collaborated on a randomized clinical trial. Furthermore, TTVguideIT was the first academic study to be submitted to the EU's Clinical Trials Information System.
Scientifically, the study breaks new ground on multiple fronts: it is the first study in which immunosuppression following organ transplantation was controlled using a biomarker, and the first multicenter biomarker study in the field of organ transplantation to achieve its primary endpoint.
Next steps and ongoing research
The findings currently apply to stable, low-risk adult kidney transplant recipients in the first year following transplantation. Whether the approach can be extended to other patient groups, later post-transplant periods, or other organ transplants remains to be investigated.
A follow-up multicenter study is already underway in France, examining the TTV-guided approach in patients from the second year post-transplant onward. The aim is to clarify whether personalized management of immunosuppression can provide additional benefits in later phases following transplantation.